Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 1.00 |
| ▸ | GLB1 | P16278 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 1.00 |
| ▸ | GUSB | P08236 | 1/20 | 0.69 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312301 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL18191975 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1894899 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1895630 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL13309999 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1894910 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL3501177 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL15704037 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL3502233 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL18191974 | 1.00 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10064851-B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | AMICUS THERAPEUTICS, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180133206-A1 | Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes | AMICUS THERAPEUTICS INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9597324-B2 | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes | AMICUS THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170027919-A1 | Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase | AMICUS THERAPEUTICS INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9402837-B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | AMICUS THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9119845-B2 | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase | Amicus Therapeautics, Inc. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150133496-A1 | Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes | AMICUS THERAPEUTICS INC (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150025109-A1 | Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase | AMICUS THERAPEUTICS INC (US) | 2015-01-22 | — | — | US | disclosed |
| US-8883813-B2 | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes | Amacus Therapeutics, Inc. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-1682504-B1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1682504-A4 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1888068-A2 | TREATMENT OF CNS DISORDERS ASSOCIATED WITH MUTATIONS IN GENES ENCODING LYSOSOMAL ENZYMES | Amicus Therapeutics, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20080009516-A1 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | AMICUS THERAPEUTICS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007150064-A2 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE | AMICUS THERAPEUTICS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2006133446-A9 | TREATMENT OF CNS DISORDERS ASSOCIATED WITH MUTATIONS IN GENES ENCODING LYSOSOMAL ENZYMES | AMICUS THERAPEUTICS INC (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060287358-A1 | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes | AMICUS THERAPEUTICS, INC. | 2006-12-21 | — | — | US | disclosed |
| WO-2006133446-A2 | TREATMENT OF CNS DISORDERS ASSOCIATED WITH MUTATIONS IN GENES ENCODING LYSOSOMAL ENZYMES | AMICUS THERAPEUTICS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1682504-A2 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | Amicus Therapeutics Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050130972-A1 | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005046612-A2 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025109-A1 | Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase | GBA3, GBA1, GALC | GBA1 2/4885GLB1 12/4885GBA2 4/4885 |
| US-20080009516-A1 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GBA3, GBA1, GALC | GBA1 2/4885GLB1 12/4885GBA2 4/4885 |
| US-20060287358-A1 | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes | GBA1, GAA, GBA2 | GBA1 1/4885GLB1 70/4885GBA2 3/4885 |
| US-20150133496-A1 | Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes | GBA1, GAA, GBA2 | GBA1 1/4885GLB1 70/4885GBA2 3/4885 |
| US-10064851-B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | GBA3, GBA1, GALC | GBA1 2/4885GLB1 12/4885GBA2 4/4885 |
| US-20170027919-A1 | Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase | GBA3, GBA1, GALC | GBA1 2/4885GLB1 12/4885GBA2 4/4885 |
| US-20180133206-A1 | Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes | GBA1, GAA, GBA2 | GBA1 1/4885GLB1 70/4885GBA2 3/4885 |
| US-20050130972-A1 | Hydroxy piperidine derivatives to treat gaucher disease | GBA1, GAA, GBA2 | GBA1 1/4885GLB1 60/4885GBA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.